Development of a malaria vaccine

Lancet

Volumn 350, Issue 9092, 1997, Pages 1696-1701

  Kwiatkowski, Dominic ^a   Marsh, Kevin ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MALARIA VACCINE; PARASITE ANTIGEN; SYNTHETIC PEPTIDE;

ANIMAL MODEL; ANTIGENIC VARIATION; CLINICAL TRIAL; HUMAN; LIFE CYCLE; MALARIA; MOSQUITO; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION; VACCINE PRODUCTION;

EID: 0031566837     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03256-X     Document Type: Review

References (57)

1. World Health Organization. World malaria situation in 1992. Part I. WkIy Epidemiol Rec 1994; 69: 309-14.
2. Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997; 349: 1650-54.
3. Boyd MF, Kitchen SF. On the efficiency of the homologous properties of acquired immunity to Plasmodium vivax, Am J Trop Med 1936; 16: 447-57.
4. Good MF. A malaria vaccine strategy based on the induction of cellular immunity. Immunol Today 1992; 13: 126-29.
5. Ellis J, Ozaki LS, Gwadz RW, et al. Cloning and expression of E coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 1983; 302: 536-38.
6. Patarroyo ME, Romero P, Torres ML, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987; 328: 629-32.
7. Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CDS+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996; 183: 1739-46.
8. Hill AV, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360: 434-39.
9. Aidoo M, Lalvani A, Allsop CE, et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995; 345: 1003-07.
10. Herrington DA, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987; 328: 257-59.
11. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992; 89: 358-62.
12. Allsopp CE, Plebanski M, Gilbert S, et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996; 26: 1951-59.
13. Gonzalez C, Hone D, Noriega FR, et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 1994; 169: 927-31.
14. Tine JA, Lanar DE, Smith DM, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996; 64: 3833-44.
15. Hoffman SL, Doolan DL, Sedegah M, et al. Nucleic acid malaria vaccines. Current status and potential. Ann N Y Acad Sci 1995; 772: 88-94.
16. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266: 169-77.
17. Edelman R, Hoffman SL, Davis JR, et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 1993; 168: 1066-70.
18. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980; 151: 1504-13.
19. Godson GN, Ellis J, Svec P, Schlesinger DH, Nussenzweig V. Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein. Nature 1983; 305: 29-33.
20. Tam JP, Clavijo P, Lu YA, Nussenzweig V, Nussenzweig R, Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med 1990; 171: 299-306.
21. Ballou WR, Hoffman SL, Sherwood JA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancer 1987; i: 1277-81.
22. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336: 86-91.
23. Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981; 294: 361-64.
24. Holder AA, Blackman MJ. What is the function of MSP-1 on the malaria merozoite? Parasitol Today 1994; 10: 182-84.
25. Etlinger HM, Caspers P, Matile H, Schoenfeld HJ, Stueber D, Takacs B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect Immun 1991; 59: 3498-503.
26. Kumar S, Yadava A, Keister DB, et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1995; 1: 325-32.
27. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 1996; 173: 765-69.
28. Crandall I, Sherman IW. Cytoadherence-related neoantigens on Plasmodium falciparum (human malaria)-infected human erythrocytes result from the exposure of normally cryptic regions of the band 3 protein. Parasitol 1994; 108: 257-67.
29. Baruch DI, Pasloske BL, Singh HB, et al. Cloning the P falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995; 82: 77-87.
30. Su XZ, Heatwole VM, Wertheimer SP, et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995; 82: 89-100.
31. Smith JD, Chitnis CE, Craig AG, et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995; 82: 101-10.
32. Playfair JHL, Taverne J, Bate CAW, de Souza JB. The malaria vaccine: anti-parasite or anti-disease? Immunol Today 1990; 11: 25-27.
33. Bate CAW, Kwiatkowski D. Inhibitory immunoglobulin M antibodies to tumor necrosis factor-inducing toxins in patients with malaria. Infect Immun 1994; 62: 3086-91.
34. Schofield L, Hackett F. Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med 1993; 177: 145-53.
35. Kwiatkowski D. Malarial toxins and the regulation of parasite density. Parasitol Today 1995; 11: 206-12.
36. Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993; 341: 705-10.
37. Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344: 1175-81.
38. D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995; 346: 462-67.
39. Nosten F, Luxemburger C, Kyle DE, et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996; 348: 701-07.
40. Carter R, Chen DH. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature 1976; 263: 57-60.
41. Gwadz RW. Successful immunization against the sexual stages of Plasmodium gallinaceum. Science 1976; 193: 1150-51.
42. Graves PM, Doubrovsky A, Carter R, Eida S, Beckers P. High frequency of antibody response to Plasmodium falciparum gametocyte antigens during acute malaria infections in Papua New Guinea highlands. Am J Trop Med Hyg 1990; 42: 515-20.
43. Quakyi IA, Carter R, Rener J, Kumar N, Good MF, Miller LH. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J Immunol 1987; 139: 4213-17.
44. Kaslow DC, Quakyi IA, Syin C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988; 333: 74-76.
45. Duffy PE, Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 1997; 65: 1109-13.
46. Smith T, Schellenberg JA, Hayes R. Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 1994; 13: 2345-58.
47. Hoffman SL, Edelman R, Bryan JP, et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 1994; 51: 603-12.
48. Smythe JA, Coppel RL, Brown GA, Ramasamy R, Kemp DJ, Anders RF. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci USA 1988; 85: 5195-99.
49. Khusmith S, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991; 252: 715-18.
50. Sturchler D, Berger R, Rudin C, et al. Safety, immun ogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg 1995; 53: 423-31.
51. Sim BKL, Orlandi PA, Haynes JD. Primary structure of the 175k Plasmodium falciparum erythrocyte binding antigen. J Cell Biol 1990; 111: 1877-84.
52. Collins WE, Pye D, Crewther PE, et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994; 51: 711-19.
53. Ridley RG, Takacs B, Elinger H, Scaife JG. A rhoptry antigen of Plasmodium falciparum is protective in Saimiri monkeys. Parasitol 1990; 101: 187-92.
54. Collins WE, Anders RF, Pappaioanou M, et al. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986; 323: 259-62.
55. Inselburg J, Bzik DJ, Li WB, et al. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect Immun 1991; 59: 1247-50.
56. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 1991; 174: 1203-08.
57. Kaslow DC, Isaacs SN, Quakyi IA, Gwadz RW, Moss B, Keister DB. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science 1991; 252: 1310-13.